Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

Conditions

• Bipolar 1 Disorder
• Delusional Disorder
• Early Psychosis
• Psychosis Not Otherwise Specified
• Schizoaffective Disorder
• Schizophrenia
• Schizophrenia Spectrum and Other Psychotic Disorders

Eligibility Criteria

Sex

ALL

Age

18 Years - 40 Years

Healthy Volunteers

Not accepted

Study Details

The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement patterns (Eye-Tracking), and brain electrical waves (EEG) data from individuals who have experienced these disorders in recent years. Participants will be involved for about a year, with four visits over this period. Screening procedures, lasting approximately 3 hours, include tests for drug use, a pregnancy test for eligible women, clinical interviews about feelings and experiences, psychiatric and family history interviews, and a medical history review. Research procedures for eligible participants include DNA collection, a neuropsychological test battery, EEG, eye-tracking, and MRI. These procedures will help researchers understand brain function, genetics, and cognitive abilities related to psychotic disorders. Follow-up visits at 1-month, 6-month, and 12-month intervals involve modified clinical interviews and repeating neuropsychological tests to track changes over time. Participants may opt to provide DNA samples for genetic analysis, undergo various cognitive tests, EEG to record brain waves, eye-tracking to monitor eye movements, and MRI scans to visualize brain structure. Follow-up visits at regular intervals will help researchers track changes in symptoms and cognitive function. This study provides comprehensive insight into the onset and progression of psychotic disorders and offers valuable information for patients, families, and healthcare providers involved in managing these conditions. Our goal is to better understand whether a combination of biological markers and different types of people (BT1, BT2, BT3) can help us predict how well individuals with early psychosis respond to specialized care. We expect that those in BT3 will have the best outcomes, BT2 will have intermediate outcomes, and BT1 will have the poorest outcomes. Even though BT1 and BT2 might start with similar cognitive issues, their biology might lead to different responses to treatment. This research can help us understand which treatments work best for different people with early psychosis.

Key Dates

Start date

Jan 1, 2023

Status verified

Mar 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

320 participants (estimated)

Arms

• Arm: Individuals with Early Psychosis enrolled in Coordinated Specialty Care Clinics
  In this naturalistic longitudinal study, we administer the B-SNIP biomarker batter to individuals with Early Psychosis (EP) in EP clinics with Coordinated Specialty Care treatment programs to characterize outcome trajectories and biotypes. EP individuals of both sexes, age 18-40 will be included after they meet study criteria and provide informed consent. Individuals with psychosis duration \< 4 years will be included. Individuals in this cohort of EP are diagnosed with Schizophrenia, Schizoaffective Disorder, Schizophreniform, Bipolar I Disorder with psychotic features, Delusional Disorder, Major Depressive Disorder with psychotic features, and Psychosis Not Otherwise Specified.

Primary Outcome Measure

Treatment Response [ Time Frame: From enrollment at baseline to end of study at 1 year ]

Central Contacts

• Matcheri S. Keshavan, MD
  617-754-1256
  [email protected]
• Brendan Stiltner, BA
  [email protected]

Locations (6)

Find similar trials in Hartford, CT

Related Studies

• Database Registry for Neural Network Biomarkers in Psychosis
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
• Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
  Recruiting · Yale University · New Haven, Connecticut
• Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
  PHASE3 · Recruiting · Gedeon Richter Plc. · Culver City, California
• Ocrelizumab for Psychosis by Autoimmunity
  PHASE1/PHASE2 · Recruiting · The Methodist Hospital Research Institute · Houston, Texas